Do Wall Street Analysts Like ResMed Stock?

Why It Matters

The stock’s lag highlights investor concerns despite strong earnings, while the Oura alliance could unlock new patient acquisition channels and sustain long‑term growth.

Key Takeaways

• ResMed shares down 15.3% past year, lagging S&P 500.
• Year‑to‑date decline 13.6% versus S&P 500 up 9.2%.
• New partnership with Oura links wearables to ResMed screening tools.
• Analysts forecast FY2026 EPS $11.13, a 16.5% increase.

Pulse Analysis

ResMed’s recent share performance underscores a broader disconnect between its robust product portfolio and market sentiment. While the company commands a leading position in sleep‑apnea therapy and has expanded into cloud‑based health management, its stock has fallen 15.3% over the last 12 months, starkly trailing the S&P 500’s nearly 28% rally. The underperformance is even more pronounced against the healthcare sector benchmark, which posted a 14.8% gain, suggesting investors are pricing in execution risk or competitive pressures despite consistent earnings beats.

The May 19 partnership with Oura represents a strategic pivot toward consumer‑driven health data. By integrating Oura’s wearable metrics with ResMed’s diagnostic tools, the firm can identify potential sleep‑apnea cases earlier, funneling users into its treatment ecosystem. This collaboration not only broadens ResMed’s addressable market beyond traditional sleep clinics but also aligns with the industry’s shift toward preventive, data‑rich care models. Early detection is likely to increase demand for continuous positive airway pressure devices and associated digital services, creating a recurring revenue stream that could stabilize earnings.

Analyst forecasts remain optimistic, projecting a 16.5% jump in diluted EPS to $11.13 for fiscal 2026. The consensus reflects confidence in ResMed’s ability to translate its technology investments into profitable growth, especially as the Oura partnership matures. For investors, the key question is whether the company can sustain its earnings momentum while narrowing the valuation gap with peers. Continued innovation in remote monitoring and strategic alliances will be critical to turning the current share price weakness into a buying opportunity.